Navigation Links
AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com
Date:8/15/2013

Dallas, TX (PRWEB) August 15, 2013

Key R&D trends in the Acute Myeloid Leukemia market include developing therapies for the patients with greatest unmet need, particularly the elderly, developing combination therapies, and investigating new targets (i.e. FLT3) involved in the pathogenesis of AML. Despite high levels of unmet need, uptake of new drugs will be limited, as KOLs are relatively unimpressed by these agents. Therefore, ample market opportunity will remain at the end of the forecast period. To circumvent historical difficulties with regulatory approval, companies are designing early- and late-stage clinical trials more rigorously. Randomization of early-stage trials is critical, and the designation of overall survival (OS) as the primary endpoint of pivotal studies is mandatory. Despite the hype around FLT3 inhibitors, KOLs are unconvinced that these drugs will be successful as monotherapies in AML.

This new research report published in Aug 2013, “OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017” ( http://www.reportsnreports.com/reports/267301-opportunityanalyzer-acute-myeloid-leukemia-aml-opportunity-analysis-and-forecasts-to-2017.html ), focuses on the remaining opportunity in AML exclusive of the acute promyleocytic leukemia (APL) subtype. The scope of this research includes: Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management; Topline AML therapeutics market revenue from 2012–2017. Annual cost of therapy, and peak pipeline drug sales of drugs launching during this forecast period are included; Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strate
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... SOUTH SAN FRANCISCO, Calif. , May 20, ... VCYT ) today presented preliminary data demonstrating ... help distinguish idiopathic pulmonary fibrosis (IPF) from other ... bronchoscopy. The findings suggest the classifier,s potential to ... expensive surgery to resolve ambiguity in IPF diagnosis ...
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... the "Global Cell Therapy Market Outlook 2020 " ... cell therapy in tissue and regenerative medicine is expected ... other options which could help in the growth of ... segment but they are unable to form new tissue ...
(Date:5/20/2015)... DENVER , May 20, 2015  Health ... connecting short-staffed healthcare organizations with job seekers looking ... SHIFT , a new mobile and online tool ... the healthcare industry. SHIFT enables employers ... locum tenens, travel nursing, per diem and other ...
(Date:5/20/2015)... , May 20, 2015  Haemonetics Corporation (NYSE: ... President & CEO, will present at The Jefferies 2015 ... on June 1 st , 2015 at 8:30am ... Mr. Concannon,s presentation live via webcast at: ... (NYSE: HAE ) is a global healthcare company ...
Breaking Biology Technology:Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... , , , ... Choose Shrimp Alkaline Phosphatase,for Easier Heat Inactivation , ... , , Simplify dephosphorylation of 5′ ends ... Shrimp Alkaline Phosphatase completely,and irreversibly by heating at 65 C for only 15 ...
... , , ... , Polymerase chain reaction (PCR) setup typically requires,thawing of ... individual reaction tubes. ,The various handling steps, , , ... , bear the risk of contaminating the amplification,reaction and , ...
... , , Product Literature Center Articles , , ... , , ... Patterns with Improved Tools for Target Amplification , , , ... FastStart Taq DNA Polymerase and the Novel FastStart High Fidelity PCR System , ...
Cached Biology Technology:Reduce Errors and Save Time When Setting Up PCRs 2Roche Diagnostics Corporation 2Roche Diagnostics Corporation 3Roche Diagnostics Corporation 4Roche Diagnostics Corporation 5
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Researchers at Georgetown University Medical Center have discovered ... on genes that can push stem cells embedded in a ... build blood vessels to link up to the body,s blood ... published in the July 16 online issue of PLoS ...
... Although sickle cell disease is a single-gene disorder, its ... July 14 by the Proceedings of the National ... and the Dana Farber Cancer Institute (DFCI), in collaboration ... five gene variants that could potentially be helpful in ...
... 15, 2008 A new book from the Soil Science Society of ... living world of soil. Soil! Get the Inside Scoop explores how ... the air we breathe, the water we drink, the houses we ... healthy plants and food production. Written for children age 9 to ...
Cached Biology News:Vitamin A pushes breast cancer to form blood vessel cells 2Vitamin A pushes breast cancer to form blood vessel cells 3Gaining ground on sickle cell disease 2Gaining ground on sickle cell disease 3
... (OSM) is a pleiotropic cytokine produced by ... cells. OSM inhibits the growth of some ... smooth muscle and Kaposis sarcoma cell proliferation, ... density lipoprotein receptor expression on hepatoma cells. ...
... trinor Prostaglandin F2α isopropyl ester (15(R)-17-phenyl ... latanoprost-related isomer containing both a double ... (β) hydroxyl group at C-15. Similar ... ester is a potential impurity in ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
... Mouse Anti Nop1p/Fibrillarin (monoclonal) ... nucleolar protein of bakers yeast, Saccharomyces ... is essential for yeast viability and ... human homologue of Nop1p is fibrillarin ...
Biology Products: